Last reviewed · How we verify
NCT07035938
T-cell Developmental Status in Patients With Malignant Hematological Tumors
trial testing observational study in Hematologic Malignancy in 75 participants. Currently enrolling.
30 June 2028
Quick facts
| Lead sponsor | The First Affiliated Hospital of Xiamen University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 75 |
| Start date | 22 June 2025 |
| Primary completion | 30 June 2028 |
| Estimated completion | 30 June 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- observational study — full drug profile →
Conditions studied
- Hematologic Malignancy — all drugs for Hematologic Malignancy →
Sponsor
The First Affiliated Hospital of Xiamen University
Who can join
18 and older, any sex, with Hematologic Malignancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the immune status and prognosis of patients with malignant hematological tumors, thereby guiding clinical therapeutic strategies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07035938
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of observational study
Trials testing the same drug.
- NCT07497139 — Sepsis Induced Myocardial Injury in Critically Ill Children · not yet recruiting
- NCT07379567 — BREVOC Study: Exhaled VOCs for High-Risk Chest Pain in the ED · not yet recruiting
- NCT07391007 — Integrated Clinical-molecular Risk Stratification to Early Recurrence in Colorectal Liver Metastases · not yet recruiting
- NCT07372183 — Wound Healing Following Extraction and Ridge Preservation in Smokers and Non-smokers · not yet recruiting
- NCT07310186 — Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy · not yet recruiting
Other recruiting trials for Hematologic Malignancy
Currently open trials in the same condition.
- NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
- NCT07511127 — Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT · Phase 3 · recruiting
- NCT07413991 — Expressive Writing Program Among Young Adults With Blood Cancer · NA · active not recruiting
- NCT06487247 — HEME Home Transfusion Program · NA · recruiting
- NCT06989489 — Implementation of an Oral Chemotherapy Adherence Intervention · NA · recruiting
Other The First Affiliated Hospital of Xiamen University trials
Trials by the same sponsor.
- NCT06875063 — GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL · Phase 1 · recruiting
- NCT07486492 — Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer · EARLY_PHASE1 · not yet recruiting
- NCT07458906 — DLL3-Targeted PET/CT in Neuroendocrine Carcinoma · NA · recruiting
- NCT07137052 — Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinomar · not yet recruiting
- NCT07189884 — Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07035938 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Xiamen University
- Last refreshed: 23 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07035938.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing